NASDAQ:NTGN - Neon Therapeutics Stock Price, Forecast & News

Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN."

Neon Therapeutics Inc (NASDAQ:NTGN) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.04. View Neon Therapeutics' Earnings History.

Neon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Neon Therapeutics.

6 brokerages have issued 12 month price objectives for Neon Therapeutics' stock. Their forecasts range from $2.18 to $15.00. On average, they anticipate Neon Therapeutics' stock price to reach $10.24 in the next twelve months. This suggests a possible upside of 481.6% from the stock's current price. View Analyst Price Targets for Neon Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neon Therapeutics.

Headlines about NTGN stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neon Therapeutics earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Neon Therapeutics.

Neon Therapeutics saw a drop in short interest in December. As of December 31st, there was short interest totalling 573,900 shares, a drop of 19.6% from the December 15th total of 713,900 shares. Based on an average daily trading volume, of 204,700 shares, the short-interest ratio is currently 2.8 days. Approximately 4.0% of the company's stock are short sold. View Neon Therapeutics' Current Options Chain.

Some companies that are related to Neon Therapeutics include LogicBio Therapeutics (LOGC), Solid Biosciences (SLDB), Dyadic International (DYAI), Applied Genetic Technologies (AGTC), Windtree Therapeutics (WINT), Erytech Pharma (ERYP), X4 Pharmaceuticals (XFOR), Fennec Pharmaceuticals (FENC), Axcella Health (AXLA), Cidara Therapeutics (CDTX), Gamida Cell (GMDA), Polarityte (PTE), Champions Oncology (CSBR), Acorda Therapeutics (ACOR) and Brainstorm Cell Therapeutics (BCLI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include AT&T (T), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Strongbridge Biopharma (SBBP), Bank of America (BAC), Anavex Life Sciences (AVXL), Bellicum Pharmaceuticals (BLCM), Enphase Energy (ENPH), Galmed Pharmaceuticals (GLMD) and Opko Health (OPK).

(NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager.

Neon Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.88%). Company insiders that own Neon Therapeutics stock include Access Industries Holdings Llc and Richard Gaynor. View Institutional Ownership Trends for Neon Therapeutics.

NTGN stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Neon Therapeutics.

Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NTGN stock can currently be purchased for approximately $1.76.

Neon Therapeutics has a market capitalization of $49.88 million. The company earns $-76,930,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe.View Additional Information About Neon Therapeutics.

The official website for Neon Therapeutics is http://www.neontherapeutics.com/.

Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected]